Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype. 400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol. Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).
• Age ≥18 years at the time of study entry.
• Diagnosis of one of the following rare sarcoma subtype, confirmed by RRePS network:
‣ Clear Cell Sarcoma (CCS)
⁃ Epithelioid Sarcoma (ES)
⁃ Perivascular Epithelioid Cell neoplasm (PEComa)
⁃ Desmoplastic Small Round Cell Tumours (DSRCT)
⁃ Malignant Solitary Fibrous Tumours (mSFT)
⁃ Alveolar Soft Part Sarcoma (ASPS)
⁃ Epithelioid Hemangioendothelioma (EH)
⁃ Low-Grade Fibromyxoid Sarcoma (LGFS)
⁃ Sclerosing Epithelioid Fibrosarcoma (SEF).
• Localized/locally advanced or metastatic disease.
• In case of localized disease, treatment must not have been yet initiated before inclusion (except surgical excision).
• In case of metastatic disease, project of new line of systemic treatment must have been decided before inclusion.
• Patient followed in the center within a standard of care procedure or clinical trial.
• Archived tumor specimen at initial diagnosis available (before treatment initiation).
• Evaluable disease (measurable as per RECIST 1.1) or not.
• ECOG Performance status 0-3.
⁃ Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.
⁃ Patient affiliated to a Social Health Insurance in France.